NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy
OUR WAR AGAINST CANCER
Harnessing Nature’s Immune System

LEARN MORE

NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy
OUR WAR AGAINST CANCER
Harnessing Nature’s Immune System

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

Image is not available

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Image is not available

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting
t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

Image is not available
previous arrow
next arrow
Slider

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

RECENT NEWS

NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of Off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-l1 Checkpoint Inhibitor Therapy

Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma PatientsCULVER CITY, CA  –January 9, 2019 - NantKwest Inc....

read more

Recent News

NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of Off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-l1 Checkpoint Inhibitor Therapy

Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma PatientsCULVER CITY, CA  –January 9, 2019 - NantKwest Inc....

read more

CONTACT NANTKWEST
CLICK HERE

NK-92 ®️ CELLS FOR ASSAYS
CLICK HERE